Supply Chain Management in the Drug Industry: Delivering Patient Value for Pharmaceuticals and Biologics

by Hedley Rees

This book bridges the gap between practitioners of supply-chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply-chains within the globally important pharmaceutical sector. Scientific and technical staff must work closely with supply-chain practitioners and other relevant parties to help secure responsive, cost effective and risk mitigated supply chains to compete on a world stage. This should not wait until a drug has been registered, but should start as early as possible in the development process and before registration or clinical trials. The author suggests that CMC (chemistry manufacturing controls) drug development must reset the line of sight – from supply of drug to the clinic and gaining a registration, to the building of a patient value stream. Capable processes and suppliers, streamlined logistics, flexible plant and equipment, shorter cycle times, effective flow of information and reduced waste. All these factors can and should be addressed at the CMC development stage.

458 pages, Hardcover

First published February 2, 2011

About the author

Hedley Rees is a passionate advocate of paradigm shifting modernization in the pharmaceutical industry.

He authored Supply Chain Management in the Drug Industry: Delivering Patient Value for Pharmaceuticals and Biologics, J Wiley & Sons, NJ in 2011.

Hedley is also managing consultant of the strategic supply-chain management consultancy PharmaFlow Ltd.

Prior to this, Hedley held senior supply chain management positions at Bayer UK, British Biotech, Vernalis, Ortho-Clinical Diagnostics (then a J&J Company) and OSI Pharmaceuticals (now Astellas).

Hedley's early career was spent as a production and industrial engineer in the automotive, consumer durables and FMCG sectors.

He graduated from the University of Wales in production engineering, and holds an Executive MBA from Cranfield University School of Management. Affiliations and qualifications include:

• Advisory Board Member of the International Institute for Advanced Purchasing & Supply (IIAPS.)
• Editorial Board Member GMP Review (GMP = Good Manufacturing Practice).
• Former Consultant to Oxford BioMedica’s Advanced Manufacturing Supply Chain Initiative (AMSCI).
• Former member (2007 – 2011) of the UK Bio-Industry Association’s (BIAs) Manufacturing Advisory Committee.
• Former Advisory Board Member of Marken, (now part of UPS).